838 men were included in analysis, with 16.5% having a baseline testosterone level <250ng/ml. Cohorts had comparable Gleason scores, PSA>20ng/ml and metastatic staged patients. Analyses demonstrated statistically significant survival advantages for patients with low baseline testosterone (Progression Free Survival HR 1.86 and Overall Survival HR 4.85). In discussion, the author states that a multivariate analysis is the next step to try to account for possible confounders.
This study advocates for serum testosterone evaluation prior to initiation of ADT to help predict survival outcomes and possibly better counsel patients. This abstract is hypothesis generating in that it suggests that patients with lower testosterone may harbor prostate cancers with more aggressive local tumor biology. Does this result from stronger autocrine and paracrine tumors factors? Future studies will hopefully help delineate these findings.
Presenter: Anup Patel, MS, FRCS
Institution: Spire Roding Hospital, London, UK
Written By: David B. Cahn, DO, MBS, Fox Chase Cancer Center
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA